Ceramide-based therapeutics for the treatment of cancer

• Published in: Anti-cancer agents in medicinal chemistry Vol. 11; no. 9; p. 911
• Main Authors: Barth, Brian M, Cabot, Myles C, Kester, Mark
• Format: Journal Article
• Language: English
• Published: Netherlands 01.11.2011
• Subjects: Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Ceramides - administration & dosage; Ceramides - metabolism; Ceramides - therapeutic use; Drug Delivery Systems - methods; Drug Resistance, Neoplasm; Humans; Neoplasms - drug therapy; Neoplasms - metabolism
• ISSN: 1875-5992
• DOI: 10.2174/187152011797655177

The bioactive sphingolipid, ceramide, has garnered major interest as a principle regulator of cellular stress, proliferation, senescence, and death. Of particular interest to cancer biologists and clinical oncologist, dysregulated ceramide metabolism has been documented in both solid and non-solid malignancies. Moreover, most anticancer chemotherapeutics stimulate ceramide accumulation through increased ceramide synthesis or through the inhibition of ceramide catabolism. In fact, neutralization of ceramide via glycosylation or phosphorylation in malignant cells has been linked to multidrug chemoresistance. New therapeutic strategies to overcome chemoresistance focus on increasing endogenous ceramide levels by stimulating ceramide synthesis, by inhibiting ceramide neutralization, or by the direct delivery of exogenous ceramide. This review will discuss new therapeutic strategies designed specifically to modulate ceramide metabolism, as well as nanoscale delivery systems engineered to selectively deliver ceramide to cancerous cells and tissues.